(Note: Thank you for supporting businesses like the one presenting a sponsored message below and working with them through the links below which benefits Gateway Pundit. We appreciate your support!) In a recent article by Dr. Peter McCullough, he explores the evolution of GLP-1 receptor agonists and their expanding role beyond diabetes treatment. The journey began in 2005 with the FDA approval of exenatide (Byetta), setting the stage for a new class of medications that regulate blood sugar and appetite. A Timeline of GLP-1 Advancements: 2005 – Exenatide (Byetta) approved for type 2 diabetes 2010 – Liraglutide (Victoza) enters the market 2017 – Semaglutide (Ozempic & oral Rybelsus) gains approval 2022 – Tirzepatide (Mounjaro) emerges as a dual-receptor agonist These drugs influence key metabolic pathways,…
Click here to read the full article at The Gateway Pundit.
